But the researchers of an ongoing clinical trial claim rapamycin, a drug commonly used to prevent organ transplants from failing, may be able to extend a woman’s fertile years by up to five years. This is based on the early communication of results from the small pilot study they conducted, which has not yet been peer reviewed.

While it’s still too early to say whether rapamycin could be the future of fertility treatments – we’ll need to wait two years now for the clinical trial to finish – there is some reason to be optimistic about the findings they’ve reported.

But the researchers of an ongoing clinical trial claim rapamycin, a drug commonly used to prevent organ transplants from failing, may be able to extend a woman’s fertile years by up to five years. This is based on the early communication of results from the small pilot study they conducted, which has not yet been peer reviewed.

While it’s still too early to say whether rapamycin could be the future of fertility treatments – we’ll need to wait two years now for the clinical trial to finish – there is some reason to be optimistic about the findings they’ve reported.

But the researchers of an ongoing clinical trial claim rapamycin, a drug commonly used to prevent organ transplants from failing, may be able to extend a woman’s fertile years by up to five years. This is based on the early communication of results from the small pilot study they conducted, which has not yet been peer reviewed.

While it’s still too early to say whether rapamycin could be the future of fertility treatments – we’ll need to wait two years now for the clinical trial to finish – there is some reason to be optimistic about the findings they’ve reported.